OR WAIT null SECS
July 02, 2009
Some GMP agents seem to find a way to squander time, money, and common sense.
Is it good policy to pay for bad behavior?
July 01, 2009
Biopharmaceutical companies generally try to avoid paying royalties on novel technologies, including novel expression systems, in part because of the inability to predict revenue flow after a product is commercialized.
Patents are an important tool for protecting innovative products, uses or processes intended for commercialization.
The world's top 50 pharmaceutical companies accounted for prescription drug sales of $558 billion (413 billion euro) in 2008.
Are manufacturers ready to deal with the economic and logistical challenges that accompany tailored therapeutics?
June 02, 2009
Misleading the public about their investments-be it money or medicine-is unacceptable.
Follow-on biologics could unleash the potential of several industries and may even spark economic recovery.
Short-term problems in software or hardware lead to long-term manufacturing troubles.
May 02, 2009
The president of BIO proposes the ingredients needed for industry growth.